
Annual report 2023
added 02-29-2024
Atrion Corporation Cash Flow 2011-2026 | ATRI
Annual Cash Flow Atrion Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
20 K | 28.8 K | 38.8 K | 39.2 M | 42.5 M | 43.2 M | 47 M | 37.4 M | 40.4 M | 31.2 M | 36.6 M | 29.4 M | 31.5 M |
Depreciation & Amortization |
15.1 K | 13.8 K | 12.9 K | 11.7 M | 10.9 M | 9.12 M | 8.68 M | 8.95 M | 8.82 M | 8.72 M | 8.59 M | 7.61 M | 6.54 M |
Accounts Payables |
6.63 K | 12.1 K | 7.15 M | 6.64 M | 5.71 M | 5.08 M | 3.93 M | 4.03 M | 3.93 M | 4.53 M | 4.09 M | 3.84 M | 3.64 M |
Accounts Receivables |
23 K | 24 K | 21 M | 16.4 M | 18.9 M | 17 M | 17.1 M | 17.2 M | 16.6 M | 17 M | 14.2 M | 13.1 M | 11.2 M |
Total Inventories |
82.3 M | 65.8 M | 50.8 M | 50.3 M | 42.1 M | 33.6 M | 29.4 M | 29 M | 29.8 M | 28 M | 26.3 M | 23.8 M | 24.6 M |
All numbers in USD currency
Quarterly Cash Flow Atrion Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | 4.33 M | - | 28.9 M | 18.3 M | 11.8 M | - | 28.8 M | 16 M | 7.4 M | - | 28.7 M | 19.4 M | 12.8 M | - | 36.2 M | 24.1 M | 12.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.08 M | - | 23.4 M | 10.9 M | 5.06 M | - | 23.8 M | 13.6 M | 7.37 M |
Depreciation & Amortization |
- | 28 K | 3.51 M | - | 10.3 M | 30 K | 3.42 M | - | 9.53 M | 6.21 M | 3.09 M | - | 8.52 M | 5.57 M | 2.76 M | - | 7.96 M | 5.21 M | 2.55 M | - | 6.7 M | 4.46 M | 2.18 M | - | 6.46 M | 4.22 M | 2.1 M | - | 6.66 M | 4.44 M | 2.21 M | - | 6.66 M | 4.5 M | 2.17 M | - | 6.7 M | 4.46 M | 2.26 M | - | 6.39 M | 4.27 M | 2.14 M | - | 5.56 M | 3.56 M | 1.72 M | - | 4.86 M | 3.16 M | 1.57 M |
Accounts Payables |
- | 199 K | 3.4 M | - | - | - | - | 7.15 M | - | - | - | 6.64 M | - | - | - | 5.71 M | - | - | - | 5.08 M | - | - | - | 3.93 M | - | - | - | 4.03 M | - | - | - | 3.93 M | - | - | - | 4.53 M | - | - | - | 4.09 M | - | - | - | 3.84 M | - | - | - | 3.64 M | - | - | - |
Accounts Receivables |
23.3 M | 23.7 M | 19.4 M | - | 22 M | 27.5 M | 24.2 M | 21 M | 25.2 M | 22.7 M | 20.2 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 18.9 M | 18.9 M | 18.9 M | 21.2 M | 17 M | 17 M | 17 M | 17 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 17 M | 17 M | 17 M | 17 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M |
Total Inventories |
82.9 M | 80.3 M | 75.1 M | - | 59.6 M | 54.3 M | 51.4 M | 50.8 M | 47.3 M | 47.7 M | 49.5 M | 50.3 M | 50.3 M | 50.3 M | 50.3 M | 42.1 M | 42.1 M | 42.1 M | 42.1 M | 33.6 M | 33.6 M | 33.6 M | 33.6 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29 M | 29 M | 29 M | 29 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M | 28 M | 28 M | 28 M | 28 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Atrion Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Becton, Dickinson and Company
BDX
|
$ 154.51 | -1.17 % | $ 44.4 B | ||
|
Repligen Corporation
RGEN
|
$ 117.78 | -0.46 % | $ 6.56 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 9.4 | -11.74 % | $ 22.8 M | ||
|
Haemonetics Corporation
HAE
|
$ 56.83 | 1.05 % | $ 2.86 B | ||
|
ICU Medical
ICUI
|
$ 123.31 | -1.53 % | $ 3.04 B | ||
|
Intuitive Surgical
ISRG
|
$ 452.07 | -2.67 % | $ 161 B | ||
|
Harvard Bioscience
HBIO
|
$ 5.2 | 2.16 % | $ 231 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
AngioDynamics
ANGO
|
$ 10.31 | -13.65 % | $ 421 M | ||
|
Repro Med Systems
KRMD
|
$ 4.32 | 1.17 % | $ 200 M | ||
|
AtriCure
ATRC
|
$ 29.07 | 2.68 % | $ 1.39 B | ||
|
Pulse Biosciences
PLSE
|
$ 23.0 | -0.13 % | $ 1.55 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.29 | -0.11 % | $ 192 M | ||
|
Masimo Corporation
MASI
|
$ 178.59 | 0.33 % | $ 9.52 B | ||
|
iRhythm Technologies
IRTC
|
$ 116.8 | -1.2 % | $ 3.74 B | ||
|
Merit Medical Systems
MMSI
|
$ 67.7 | -0.78 % | $ 4 B | ||
|
BioLife Solutions
BLFS
|
$ 19.51 | 1.14 % | $ 899 M | ||
|
electroCore
ECOR
|
$ 6.8 | 3.03 % | $ 57.7 K | ||
|
STERIS plc
STE
|
$ 218.71 | -0.56 % | $ 21.6 B | ||
|
Teleflex Incorporated
TFX
|
$ 117.81 | -0.52 % | $ 5.26 B | ||
|
Utah Medical Products
UTMD
|
$ 63.12 | 0.4 % | $ 205 M | ||
|
OraSure Technologies
OSUR
|
$ 3.08 | 0.98 % | $ 226 M | ||
|
West Pharmaceutical Services
WST
|
$ 254.8 | 0.82 % | $ 18.4 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.63 | -0.26 % | $ 2.32 B | ||
|
Glaukos Corporation
GKOS
|
$ 112.77 | 0.12 % | $ 5.46 B | ||
|
ResMed
RMD
|
$ 224.09 | 0.56 % | $ 32.7 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
Baxter International
BAX
|
$ 16.68 | -0.6 % | $ 8.56 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
STAAR Surgical Company
STAA
|
$ 20.21 | 4.55 % | $ 1 B | ||
|
Stereotaxis
STXS
|
$ 1.87 | 1.08 % | $ 170 M | ||
|
The Cooper Companies
COO
|
$ 70.17 | -1.76 % | $ 14 B | ||
|
LeMaitre Vascular
LMAT
|
$ 108.49 | -0.24 % | $ 2.46 B | ||
|
Microbot Medical
MBOT
|
$ 2.4 | 1.27 % | $ 110 M | ||
|
Nephros
NEPH
|
$ 2.87 | -2.21 % | $ 29.8 M | ||
|
Envista Holdings Corporation
NVST
|
$ 25.81 | -0.35 % | $ 4.34 B | ||
|
Milestone Scientific
MLSS
|
$ 0.28 | -4.86 % | $ 23 M | ||
|
Alcon
ALC
|
$ 74.56 | -1.26 % | $ 40.4 B | ||
|
Pro-Dex
PDEX
|
$ 51.67 | 1.33 % | $ 170 M | ||
|
Retractable Technologies
RVP
|
$ 0.69 | 2.99 % | $ 20.7 M |